Neogen (NEOG) Stock Analysis & AI Equity Report

Medical - Diagnostics & Research USD Explore free reports

Neogen (NEOG) overview

Neogen (NEOG) stock analysis and AI equity research. For financial year 2026, Valuatum's model shows revenue of USD 870m and operating profit of USD -21.6m; the year-end share price was 8.97 USD and market capitalisation was USD 1,953m. Neogen is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Neogen's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 2,093mFY 2026
Share price8.97 USDFY 2026 year end
RevenueUSD 870mFY 2026
Operating profitUSD -21.6mFY 2026
Net earningsUSD -7.9mFY 2026
Market capitalisationUSD 1,953mFY 2026 year end

About Neogen

Neogen develops, manufactures, and markets products and services for food and animal safety. Its food-safety offerings include diagnostic test kits, consumables, culture media, and software for detecting contaminants and assessing food quality, sold to producers, processors, laboratories, and regulatory agencies. Animal-safety products include veterinary instruments, medicines, vaccines, diagnostics, pest-control products, genomics testing, and drug-detection solutions distributed through industry channels.

Generate the Neogen report

Neogen is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Neogen and represent financial year 2026. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Neogen

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.